 - Patients may have received prior chemotherapy, crizotinib other ALK inhibitors are not allowed, biologic therapy or other investigational agents. Patients must have recovered from all toxicities related to prior anticancer therapies to grade 1 CTCAE v 4.03. Patients with any grade of alopecia are allowed to enter the study. 